Subscribe
Wirestock Creators / Shutterstock.com
19 November 2024NewsAmericasSarah Speight

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

US Supreme Court blocks bid to overturn lower court ruling | District court found in 2023 that the generic would infringe patents owned by a Bausch subsidiary | Blockbuster drug Xifaxan is used to treat IBS with diarrhoea, and a liver-related brain disorder.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Setback for Alvogen in approval bid for IBS generic
2 November 2023   District court denies Norwich’s motion to compel FDA to grant approval for its version of popular IBS medication | Court also grants summary judgment in favour of FDA and Norwich’s competitor.


Editor's picks

Americas
Comparing life sciences IP in Brazil and the US
28 November 2024

Editor's picks

Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024

More on this story

Generics
Setback for Alvogen in approval bid for IBS generic
2 November 2023   District court denies Norwich’s motion to compel FDA to grant approval for its version of popular IBS medication | Court also grants summary judgment in favour of FDA and Norwich’s competitor.

More on this story

Generics
Setback for Alvogen in approval bid for IBS generic
2 November 2023   District court denies Norwich’s motion to compel FDA to grant approval for its version of popular IBS medication | Court also grants summary judgment in favour of FDA and Norwich’s competitor.

More features

Gene tech firm fends off injunction in test kit dispute
Comparing life sciences IP in Brazil and the US
Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal